Novo Nordisk Takes Legal Action Against Hims & Hers Over Wegovy Knock Offs

Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.Novo Nordisk’s Legal Move ExplainedNovo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.Hims c ...